Obesity Icon in white

Obesity

Explore facts and recommendations for pharmacological treatments for obesity.

pharmacotherapies
Filters

We are still gathering material for this library.

Please check again soon.

We're sorry

We didn't find any resources that match your selection.

Please adjust your filter(s) and try again.

pharmacotherapies
 
Preview
obesity PDF

Wegovy® (semaglutide) Injection Dosing – Guidelines

Wegovy® Dosing Guidelines. Wegovy® should be initiated at a dose of 0.25 mg once weekly for 4 weeks. The dose should be increased in 4-week intervals (0.25 mg, 0.5 mg, 1 mg, 1.7 mg) until the maintenance dose of 2.4 mg is reached.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
obesity Video

Wegovy® (semaglutide) injection Mode of Action in Obesity

This video discusses the mechanism of action of Wegovy®

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
continuing education icon

Continuing Education

Find accredited opportunities in obesity education.

Explore CE Activities
pharmacotherapies
 
Preview
obesity PDF

Current Recommendations for Weight-Loss Medications as Part of Obesity Management (IME content)

Snapshot of why medication is a powerful tool in obesity management.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
obesity PDF

Overview of the STEP Clinical Development Program for Wegovy® (semaglutide) Injection

Information about Wegovy’s® STEP 1-4 clinical trials. These trials were built to evaluate its safety and efficacy for weight management in adult patients living with obesity and weight-related comorbidities.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
obesity PDF

STEP 1 Clinical Trial: Weight Management with Wegovy® (semaglutide) Injection

Results of a 68-week trial comparing weight loss while receiving Wegovy® or placebo in 1961 adults with obesity or overweight.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
obesity PDF

STEP 2 Clinical Trial: Weight Management with Wegovy® (semaglutide) Injection in Adults with Type 2 Diabetes

Findings of a 68-week trial comparing Wegovy® vs placebo vs semaglutide injection 1.0 mg in 1210 adults with overweight or obesity and Type 2 diabetes.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
obesity PDF

STEP 3 Clinical Trial: Weight Management with Wegovy® (semaglutide) Injection and Intensive Behavioral Therapy (IBT)

Outcomes of a 68-week trial comparing Wegovy® vs placebo in combination with IBT in 611 adults with obesity or overweight and at least 1 weight-related comorbidity.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
obesity PDF

STEP 4 Clinical Trial: Sustained Weight Management with Wegovy® (semaglutide) Injection

Findings of a 68-week trial comparing sustained weight management in adults with obesity or overweight and at least 1 weight-related comorbidity while receiving Wegovy® or placebo.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close

Obesity

congress materials
View Resources

Obesity

disease education
View Resources

Looking for additional resources?
Explore other libraries or search the Exchange.

Novo Nordisk® Scientific Exchange logo

Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

This medical content was developed independently by a third party via an educational grant. This material is copyright protected and is provided here with permission for educational and informational purposes only and is not certified for continuing education credits.

Continue

You are now leaving the Novo Nordisk Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

Continue

GATED INTERSTITAL  

You are now leaving the Novo Nordisk Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

ACCESS DENIED

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.